AbbVie sales exceed estimates despite Humira dip

1 November 2019
abbvie_us_large

Executives at AbbVie (NYSE: ABBV) will be pleased to see that, even with sales of its flagship product Humira (adalimumab) dipping nearly 4%, the firm’s overall revenue still increased and beat the estimates of analysts.

Shareholders seemed to share this sentiment, with the US drugmaker’s stock value up nearly 3% by early-afternoon on Friday, following the presentation of AbbVie’s third quarter 2019 results.

Overall net revenues grew by 3% from the same period in 2018, to $8.48 billion, exceeding analysts’ estimates of $8.38 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical